

## LIVER DISEASE

## Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Changyu Zhu<sup>1</sup>, KyeongJin Kim<sup>1</sup>, Xiaobo Wang<sup>1</sup>, Alberto Bartolome<sup>1</sup>, Marcela Salomao<sup>2</sup>, Paola Dongiovanni<sup>3</sup>, Marica Meroni<sup>3</sup>, Mark J. Graham<sup>4</sup>, Katherine P. Yates<sup>5</sup>, Anna Mae Diehl<sup>6</sup>, Robert F. Schwabe<sup>1</sup>, Ira Tabas<sup>1</sup>, Luca Valenti<sup>3</sup>, Joel E. Lavine<sup>7</sup>, Utpal B. Pajvani<sup>1\*</sup>

Copyright © 2018  
The Authors, some  
rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. No claim  
to original U.S.  
Government Works

Fibrosis is the major determinant of morbidity and mortality in patients with nonalcoholic steatohepatitis (NASH) but has no approved pharmacotherapy in part because of incomplete understanding of its pathogenic mechanisms. Here, we report that hepatocyte Notch activity tracks with disease severity and treatment response in patients with NASH and is similarly increased in a mouse model of diet-induced NASH and liver fibrosis. Hepatocyte-specific Notch loss-of-function mouse models showed attenuated NASH-associated liver fibrosis, demonstrating causality to obesity-induced liver pathology. Conversely, forced activation of hepatocyte Notch induced fibrosis in both chow- and NASH diet-fed mice by increasing Sox9-dependent Osteopontin (Opn) expression and secretion from hepatocytes, which activate resident hepatic stellate cells. In a cross-sectional study, we found that OPN explains the positive correlation between liver Notch activity and fibrosis stage in patients. Further, we developed a Notch inhibitor [*Nicastrin* antisense oligonucleotide (*Ncst* ASO)] that reduced fibrosis in NASH diet-fed mice. In summary, these studies demonstrate the pathological role and therapeutic accessibility of the maladaptive hepatocyte Notch response in NASH-associated liver fibrosis.

## INTRODUCTION

Obesity and its metabolic consequences are among the most pressing public health challenges (1, 2). As the obese population at risk increases (3), the prevalence of obesity-related comorbidities such as nonalcoholic fatty liver disease (NAFLD), already the most common chronic liver disease (4), grows in parallel. NAFLD ranges in severity from simple steatosis (SS) to hepatocellular injury and necroinflammatory changes that define nonalcoholic steatohepatitis (NASH), which predisposes patients to fibrosis and hepatocellular carcinoma (5). Whereas SS is considered a predisease state and NASH is potentially reversible (6), fibrosis severity is the main determinant of mortality in patients with NAFLD (7–10). Because organ availability for transplantation is already limited, new pharmaceutical targets to address NASH-associated fibrosis are a large unmet need for an increasingly obese population.

The Notch family of transmembrane receptors (Notch1–4) determines cell fate during development (11) through ligand binding and  $\gamma$ -secretase-mediated cleavage that generates Notch intracellular domain (NICD) (12), which binds Rbp-Jk and Mastermind (MAM) to activate transcription of canonical Notch targets including the *Hairy enhancer of split* (*Hes*) and *Hes-related* (*Hey*) family genes (13). In the liver, Notch activation pushes hepatic progenitor cells' differentiation to cholangiocytes and formation of the biliary tree, whereas Notch-inactive progenitors commit to hepatocyte lineage (14), which sets the quiescent baseline of Notch signaling in hepatocytes in normal liver. However, we found that liver Notch ac-

tivity is increased in obese rodents (15) and in patients with SS or NASH (16), although the relative contributions of hepatocyte and nonparenchymal cell (NPC) Notch activity were unclear.

Here, we found that the number of HES1<sup>+</sup> hepatocytes, but not of NPCs, is increased in patients with NASH. In longitudinal analysis using paired baseline and end-of-treatment biopsy specimens from the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial (17, 18), we found that Notch activity, specifically in hepatocytes, tracks with NASH severity. These data suggested that hepatocyte Notch activation may be a biomarker or a causal determinant of NASH severity. To distinguish these possibilities, we used a palmitate/cholesterol-rich diet coupled with fructose-containing drinking water (19) fed to wild-type (WT) mice to induce NASH/fibrosis, which increased hepatocyte but not NPC Notch activation. Two genetic hepatocyte-specific Notch loss-of-function mouse models showed lower hepatic stellate cell (HSC) activity and liver collagen deposition without changes in hepatocellular injury or inflammation, whereas forced activation of hepatocyte Notch induced fibrosis in chow-fed mice because of Sox9 (sex determining region Y-box 9)-dependent expression of *Spp1* (encoding the secreted fibrogenic factor Opn). Treating NASH diet-fed WT mice with a Notch antagonist [*Nicastrin* antisense oligonucleotide (*Ncst* ASO)] decreased liver fibrosis. In sum, these data support the necessity and therapeutic tractability of hepatocyte Notch signaling for the development of NASH-associated liver fibrosis.

## RESULTS

## Hepatocyte Notch activity tracks with NASH severity in patients


Steady-state liver Notch activation is associated with higher serum alanine aminotransferase and a NAFLD activity score (NAS), which are biochemical and pathologic markers of NASH, independent of steatosis or insulin resistance (16). To test relative hepatocyte and NPC

<sup>1</sup>Department of Medicine, Columbia University, New York, NY 10032, USA. <sup>2</sup>Department of Pathology, Mayo Clinic, Phoenix, AZ 85054, USA. <sup>3</sup>Department of Pathophysiology and Transplantation, Università degli Studi Milano, and Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Policlinico, Milan 20122, Italy. <sup>4</sup>Ionis Pharmaceuticals Inc., Carlsbad, CA 92010, USA. <sup>5</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. <sup>6</sup>Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. <sup>7</sup>Department of Pediatrics, Columbia University, New York, NY 10032, USA.

\*Corresponding author. Email: up2104@columbia.edu

contribution, we stained liver biopsy specimens taken at the time of bariatric surgery from patients with pathologically normal livers, SS, or NASH/fibrosis. We observed detectable basal NPC expression of HES1, which, although modestly increased in SS, did not further change in NASH/fibrosis (Fig. 1A and fig. S1). Hepatocyte HES1, however, was nearly absent in normal livers, mildly elevated in SS, but highly increased in patients with NASH/fibrosis (Fig. 1A).

Next, to determine whether liver Notch activity may covary with NASH severity and treatment response, we performed parallel cross-sectional and longitudinal analyses in samples derived from the PIVENS trial. PIVENS investigators randomized adult, nondiabetic patients with NASH to placebo, vitamin E (800 IU daily), or pioglitazone (30 mg daily) arms, taking liver biopsies at enrollment and end-of-treatment (96 weeks) visits (20). A “responder” was defined



**Fig. 1. Hepatocyte Notch activation in NASH.** (A) Representative images of HES1 (red) and hepatocyte nuclear factor 4α (HNF4α; green) immunofluorescence in liver biopsies from patients with histologically normal liver, SS, or NASH/fibrosis and quantification of the percentage of HES1<sup>+</sup> cells among HNF4α<sup>+</sup> hepatocytes and HNF4α<sup>−</sup> nonhepatocytes ( $n = 3$  to 4 per group). (B) Expression of Notch target genes *HES1* and *HEY1* after 96 weeks of treatment in nonresponders ( $n = 49$ ) or responders ( $n = 69$ ) from the PIVENS trial. (C) Liver *HES1* and (D) *HEY1* expression in paired baseline and 96-week end-of-treatment liver biopsy specimens from PIVENS subjects ( $n = 10$  to 11 per group) and (E) percentage change of HES1<sup>+</sup>/HNF4α<sup>+</sup> hepatocytes and HES1<sup>+</sup>/HNF4α<sup>−</sup> NPCs in nonresponders (NR) and responders (R) from baseline to end of treatment ( $n = 7$  per group). (F) *Hes1* expression in liver, fractionated hepatocytes, and NPCs. (G) Representative images of *Hes1* and HNF4α immunofluorescence in chow- and NASH diet-fed WT mouse livers and quantification of the percentage of hepatocytes with nuclear *Hes1* staining ( $n = 9$  per group). (H) Expression of Notch receptors in hepatocytes and (I) Western blots of Notch1 and Notch2 intracellular domains (ICDs) in livers from chow- and NASH diet-fed WT mice. (J) Quantification of Venus<sup>+</sup> hepatocytes in livers from chow- and NASH diet-fed Notch reporter mice ( $n = 5$  per group). \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  as compared to the indicated controls by two-tailed  $t$  tests (two groups) or one-way analysis of variance (ANOVA), followed by post hoc  $t$  tests (three groups). All data are shown as the means  $\pm$  SEM. NS, not significant; AU, arbitrary units.

as an NAS response of at least 2 points or resolution of NASH. In a cross-sectional analysis of 118 samples (table S1), responders showed lower liver Notch activity than nonresponders at the end of the trial (Fig. 1B). Next, in a longitudinal analysis from a subset of PIVENS subjects that had paired baseline and end-of-treatment complementary DNA (table S1), we found a reduction from baseline *HES1* and *HEY1* expression in responders but not in nonresponders (Fig. 1, C and D). Last, we found reduced hepatocyte, but not NPC, *HES1* staining in liver sections from PIVENS responders from baseline and as compared to nonresponders (Fig. 1E). In sum, these data suggest that liver Notch activity, specifically in hepatocytes, tracks with NASH disease severity.

### Hepatocyte Notch activity is increased in a mouse model of diet-induced NASH

As a first step toward determining whether a causal relationship exists between Notch activity and NASH, we fed WT C57BL/6J mice a NASH-provoking diet for 16 weeks, which induced hepatic steatosis, inflammation, and fibrosis as compared to chow-fed mice (fig. S2) (19). As in patients with NASH/fibrosis, we found higher liver and hepatocyte, but not NPC, *Hes1* in NASH diet-fed mice (Fig. 1F), reflecting an increased number of *Hes1*<sup>+</sup> hepatocytes and increased *Hes1* staining intensity per cell (Fig. 1G), consistent with increased expression and activation of *Notch1* and *Notch2* (Fig. 1, H and I). In parallel, using a Notch reporter mouse that expresses the fluorescent protein Venus under the control of four Rbp-jk binding sites (21), we found a large increase in Venus<sup>+</sup> hepatocytes in NASH diet-fed mice (Fig. 1J).

### Hepatocyte Notch mediates NASH diet-induced liver fibrosis

The positive correlations between hepatocyte Notch activation and NASH severity provided the impetus to generate hepatocyte-specific Notch loss-of-function mice to test causality to the phenotype. Because the MAM transcriptional coactivator is downstream of all four Notch receptors, we transduced mice with a dominant-negative MAM (DNMAM) allele (22) in the *Rosa26* locus (*Rosa*<sup>DNMAM</sup>) with AAV8-*Tbg-Cre* to take advantage of liver tropism of AAV8 and the hepatocyte-specific thyroxine-binding globulin (*Tbg*) promoter (23, 24). This approach generated mice with postdevelopment hepatocyte-specific expression of DNMAM (*L-DNMAM* mice; Fig. 2A). After 16 weeks of NASH diet, *L-DNMAM* mice showed similar body weight and adiposity (fig. S3, A and B) as compared with control *Rosa*<sup>DNMAM</sup> mice transduced with AAV8-*TBG-LacZ* but lower liver *Hes1* expression (Fig. 2B), fewer *Hes1*<sup>+</sup> hepatocytes, and weaker *Hes1* staining intensity per cell (Fig. 2C and fig. S3C). Despite unchanged liver lipid accumulation, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining, inflammatory gene expression, CD45<sup>+</sup> immune cell infiltrate, and serum transaminases (Fig. 2D and fig. S3, D to I), markers of HSC activation (*Col1a1*, *Acta2*, and *Timp1*) were decreased (Fig. 2E), which translated to less collagen deposition in *L-DNMAM* livers (Fig. 2F).

Next, to ensure reproducibility of these results, we ablated hepatocyte *Nicastrin* (25), the  $\gamma$ -secretase targeting subunit necessary for ligand-dependent Notch activation (*L-Ncst* mice) (26). Similar to *L-DNMAM* mice, NASH diet-fed *L-Ncst* mice showed normal body weight and adiposity (fig. S4, A and B), but reduced hepatic *Hes1* (fig. S4C) and fibrogenic gene expression (fig. S4D), and a tendency toward less fibrosis (fig. S4E) as compared to Cre<sup>-</sup> controls, despite unchanged

hepatic TUNEL staining or serum transaminases, liver inflammation, and only minor changes in liver lipid content (fig. S4, F to L).

These data suggest that hepatocyte Notch signaling is necessary for the full development of NASH diet-induced fibrosis. To test whether a late inhibition of Notch in hepatocytes may ameliorate NASH-associated fibrosis, we fed adult *Rosa*<sup>DNMAM</sup> mice the NASH diet for 16 weeks before AAV8-*Tbg-Cre* transduction (Fig. 2G). In this experimental paradigm, we again observed decreased liver *Hes1* (Fig. 2H) and a parallel reduction in HSC-mediated liver fibrosis (Fig. 2, I and J) despite unchanged body weight, adiposity, liver steatosis, inflammation, TUNEL staining, or serum transaminases (fig. S5, A to I). These data indicate that inhibition of hepatocyte Notch signaling can interrupt NASH-associated fibrosis even after fibrosis has begun to develop.

### Hepatocyte Notch is not required for MCD diet-induced fibrosis


Acute toxin exposure increases Notch activity in HSCs and immune cells (27–29), contrary to what we find in fluorescence-activated cell sorter (FACS)-purified HSCs and myeloid cells isolated from NASH diet-fed mice (fig. S6A). Similarly, we observed that a methionine-choline deficient (MCD) diet, which induces severe liver injury, inflammation, and fibrosis in addition to anorexia and rapid weight loss (30, 31), led to increased liver *Hes1* expression relative to chow-fed controls (fig. S6B). This increased *Hes1* expression was predominantly seen in NPCs (fig. S6C), unlike in NASH diet feeding (fig. S6D). These data are consistent with a recent study showing unchanged expression of Notch targets in hepatocytes in MCD diet-fed mice (32) and with our finding that MCD diet-fed *L-DNMAM* mice show no difference in liver *Hes1* and fibrogenic gene expression or collagen deposition (fig. S6, E to H), suggesting specificity of the hepatocyte Notch response in NASH.

### Forced hepatocyte Notch activation exacerbates diet-induced NASH and fibrosis

We next evaluated whether forced hepatocyte Notch activation by AAV8-*TBG-Cre* transduction of mice that carry a Cre-inducible constitutively active (*Rosa*<sup>NICD</sup>) Notch1 (33) may exacerbate NASH/fibrosis (*L-NICD*-16wks, Fig. 3A). In parallel, because 8 weeks of NASH diet provoke steatosis but no apparent fibrosis (19), we transduced *Rosa*<sup>NICD</sup> mice with AAV8-*TBG-Cre* halfway through the diet study (*L-NICD*-8wks, Fig. 3A) to determine whether hepatocyte Notch activity promotes the transition from steatosis to NASH/fibrosis. As compared to AAV8-*TBG-LacZ*-transduced *Rosa*<sup>NICD</sup> controls, both *L-NICD* groups showed a mild (~2-fold) increase in liver *Hes1* due to increased *Hes1*<sup>+</sup> hepatocyte number and cellular *Hes1* content (Fig. 3, B and C, and fig. S7A), as well as increased HSC activation and pericellular collagen deposition (Fig. 3, D and E), even with a mild decrease of liver triglyceride (fig. S7, B and C). Hepatocyte Notch gain of function also did not change hepatocellular death (Fig. 3F), underscoring the predominant effects of hepatocyte Notch activation on liver fibrosis development but did show enhanced liver inflammation and CD45<sup>+</sup> immune cell infiltration (fig. S7, D and E).


Although NASH is prevalent in both male and female humans (34), female mice tend to be protected from diet-induced obesity and consequent metabolic complications. Consistent with their male counterparts, despite unchanged body weight and adiposity (fig. S7, F and G), female *L-NICD* mice showed increased liver *Hes1*, inflammatory and fibrogenic gene expression (fig. S7, H to J), and





**Fig. 2. Hepatocyte Notch blockade ameliorates NASH-associated fibrosis.** (A) *Rosa<sup>DNMAM</sup>* mice (8 weeks old) were transduced with AAV8-TBG-LacZ (control) or AAV8-TBG-Cre to generate *L-DNMAM* mice and then fed for 16 weeks with NASH diet ( $n = 9$  to 10 per group). (B) *Hes1* expression and (C) representative images of *Hes1* (red) and HNF4 $\alpha$  (green) staining, (D) TUNEL (red) staining and quantification, (E) expression of fibrogenic genes, and (F) liver collagen staining and quantification in livers from Cre<sup>-</sup> control and *L-DNMAM* mice. DAPI, 4',6-diamidino-2-phenylindole. (G) *Rosa<sup>DNMAM</sup>* mice (8 weeks old) were fed with NASH diet for 32 weeks with AAV8-TBG-LacZ or AAV8-TBG-Cre transduction in the 16th week ( $n = 9$  per group). (H) *Hes1* and (I) fibrogenic gene expression, and (J) collagen staining and quantification in livers from Cre<sup>-</sup> controls and mice with delayed expression of *DNMAM*. \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  as compared to the indicated controls by two-tailed  $t$  tests (two groups). All data are shown as the means  $\pm$  SEM.






**Fig. 3. Hepatocyte Notch activation exacerbates NASH and fibrosis.** (A) *Rosa<sup>NICD</sup>* mice (8 weeks old) were transduced with AAV8-TBG-LacZ (control) or AAV8-TBG-Cre to generate hepatocyte-specific Notch gain-of-function (*L-NICD-16wks*) mice before 16 weeks of NASH diet feeding or halfway through NASH diet feeding (*L-NICD-8wks*) ( $n = 9$  to 11 per group). (B) *Hes1* expression and (C) representative images of *Hes1* (red) and *HNF4α* (green) staining, (D) expression of fibrogenic genes, (E) collagen staining and quantification, and (F) TUNEL (red) staining in livers from control and *L-NICD* mice. \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  as compared to Cre<sup>-</sup> control mice by one-way ANOVA, followed by post hoc *t* tests (three groups). All data are shown as the means  $\pm$  SEM.

exacerbated liver inflammation and fibrosis as compared to AAV8-TBG-LacZ-transduced controls (fig. S7, K and L).

### Hepatocyte Notch activation causes liver fibrosis in the absence of steatohepatitis

NASH is associated with simultaneous pathologic insults: lipotoxicity, hepatocellular injury, inflammation, and fibrosis. Each hit may

affect development and/or progression of the others (35, 36); for example, lipotoxicity-induced hepatocellular injury contributes to HSC activation (37, 38). Although we observed unchanged hepatocellular death in Notch loss- or gain-of-function mice, it is difficult to disentangle the effects of hepatocyte Notch on liver fibrosis from other changes associated with an obesogenic diet. However, even lean, chow-fed *L-NICD* male mice (Fig. 4A and fig. S8, A to C),



**Fig. 4. Hepatocyte Notch activation in chow-fed mice induces Sox9-dependent *Spp1* expression and liver fibrosis.** (A) Male normal chow-fed *Rosa<sup>NICD</sup>* mice (8 weeks old) were transduced with AAV8-TBG-LacZ (control) or AAV8-TBG-Cre (*L-NICD*) and maintained on normal chow diet for 16 more weeks ( $n = 6$  to 8 per group). (B) Quantification of TUNEL staining, (C) fibrogenic gene expression, and (D) collagen staining and quantification in livers from control and *L-NICD* mice. (E) Fibrogenic gene expression in plated HSCs isolated from WT mice, exposed to control or Ad-NICD-transduced hepatocyte conditioned medium (CM;  $n = 3$  per group). (F) *Hes1* and *Spp1* in control and Notch-activated primary hepatocytes ( $n = 6$  per group). (G to J) *Spp1* expression in (G) livers and isolated hepatocytes of NASH diet-fed mice ( $n = 9$  per group), (H) hepatocytes sorted on the basis of Notch activity from Notch reporter mice ( $n = 13$  per group), (I) livers and FACS-separated hepatocytes from NASH diet-fed *L-DNMM* mice ( $n = 8$  per group), and (J) NASH diet-fed *L-NICD* mice ( $n = 7$  per group). (K) *Spp1* expression in siSox9- or siHes1-transfected primary hepatocytes ( $n = 3$  per group). \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  as compared to the indicated controls by two-tailed *t* tests (two groups) or one-way ANOVA, followed by post hoc *t* tests (more than two groups). All data are shown as the means  $\pm$  SEM.

without apparent hepatocellular injury (Fig. 4B and fig. S8, D and E), showed increased liver inflammation (fig. S8, F and G), fibrogenic gene expression (Fig. 4C), and greater collagen deposition (Fig. 4D) than Cre<sup>-</sup> controls. This phenotype was recapitulated in *L-NICD* female mice (fig. S9). These data suggest that hepatocyte Notch activation is sufficient to trigger HSC activation and liver fibrosis even in the absence of liver steatosis or hepatocyte injury.

#### Loss of hepatocyte Notch activity does not affect DRs

Notch activation in hepatocytes may promote transdifferentiation to a cholangiocyte lineage (23, 39), contributing to ductular reaction (DR). Because DR and liver fibrosis frequently coexist (40–43), we hypothesized that Notch-induced liver fibrosis may depend on Notch-induced DR. NASH diet induced ductular proliferation, as evidenced by increased liver *Krt19* expression and number of cytokeratin



19-positive (CK19<sup>+</sup>) cells (fig. S10, A and B), which was exacerbated in *L-NICD* mice (fig. S10, C and D). Further, as previously observed (23), a subset of *L-NICD* hepatocytes adopted a biliary fate (fig. S10E). However, NASH diet-fed Notch loss-of-function mice showed comparable DR to controls (fig. S10, F and G). These data suggest that constitutive Notch overexpression can induce hepatocyte trans-differentiation, but hepatocyte Notch activation is not necessary for NASH diet-induced DR that likely derives from cholangiocytes.

### Notch-induced Sox9 activates hepatocyte *Spp1* expression

We next considered alternative explanations for the robust effect of hepatocyte Notch on liver fibrosis and hypothesized that Notch-active hepatocytes may secrete fibrogenic factors that activate HSCs (44). CM collected from primary hepatocytes transduced with Ad-NICD stimulated greater activation of primary HSCs as compared to Ad-GFP (green fluorescent protein)-transduced hepatocyte CM (Fig. 4E). Notch activation did not globally affect the secretome but elevated secretion of the fibrogenic factor Opn (fig. S11A), likely because of increased *Spp1* expression (Fig. 4F). Although Opn is known to activate HSCs (45–48), hepatocyte-derived Opn has not been well described. We found that *Spp1* was increased in hepatocytes derived from NASH diet-fed WT mice (Fig. 4G), with a preferential increase in Venus<sup>+</sup> hepatocytes in Notch reporter mice (Fig. 4H). Thus, NASH diet-fed *L-DNMAM* mice showed lower *Spp1* as compared to Cre<sup>-</sup> controls (Fig. 4I), whereas *Spp1* expression was markedly increased in chow- or NASH diet-fed *L-NICD* mice (Fig. 4J and fig. S11, B and C). This regulation appeared fairly specific: Similar to results from the cytokine array, expression of other secreted fibrogenic factors (Hedgehog, transforming growth factor- $\beta$ , and platelet-derived growth factors) was not Notch-activated in hepatocytes (fig. S11D) and/or does not show reciprocal reduction with Notch loss of function (fig. S11E).

These data suggest a cell-autonomous effect of hepatocyte Notch activation on *Spp1* transcription. Because the *Spp1* promoter does not have a consensus Rbp-Jk binding sequence, we identified additional candidates—Sox9, a direct Notch transcriptional target (49), which we observed to track with genetic manipulations of Notch signaling (fig. S11, F to I), and *Hes1*, which has been suggested to regulate *Spp1* expression in osteoblasts (50). To distinguish between these candidate mechanisms, we used small interfering RNA (siRNA) to knock down *Hes1* or *Sox9* expression and found that only siRNA directed to *Sox9* blunted NICD-induced *Spp1* (Fig. 4K), suggesting that Sox9 is the transcriptional mediator of Notch-induced *Spp1* expression in hepatocytes.

### Notch-mediated Opn secretion from hepatocytes activates HSCs to induce liver fibrosis

To determine whether increased Opn secretion may explain HSC activation induced by hepatocyte Notch activation, we transfected hepatocytes with siRNA to *Spp1* (Fig. 5, A and B, and fig. S11J), which abrogated HSC activation induced by Ad-NICD hepatocyte CM (Fig. 5C). In a parallel approach, we pretreated CM with an Opn-neutralizing antibody before addition to HSCs, which similarly negated Notch-induced fibrogenic gene expression (Fig. 5D).

Next, we generated AAV8-H1-sh*Spp1* to silence hepatocyte *Spp1* and transduced adult NASH diet-fed *Rosa<sup>NICD</sup>* mice with AAV8-TBG-*Gfp* or AAV8-TBG-*Cre*, with or without simultaneous *Spp1* knockdown (Fig. 5E). AAV8-H1-sh*Spp1* transduction did not affect body weight, adiposity, *Hes1* expression, liver injury, or inflamma-

tory gene expression (fig. S12, A to F) but successfully attenuated Notch-induced hepatocyte *Spp1* without affecting cholangiocyte Opn (Fig. 5F and fig. S12, G and H). Consistent with in vitro experiments, preventing Notch-induced hepatocyte *Spp1* expression nearly normalized increased fibrogenic gene expression (Fig. 5G) and excess collagen deposition seen in NASH diet-fed *L-NICD* mice (Fig. 5H).


To test the clinical importance of this observation, we analyzed expression of hepatic *SPP1* and *HES1* in 159 patients undergoing percutaneous liver biopsy for suspected NASH (table S2). We observed a strong concordance between *HES1* and *SPP1* (Fig. 5I). Moreover, when we performed multivariate regression analysis to adjust for potential demographic, metabolic, and genetic confounders, *HES1* was significantly ( $P = 0.016$ ) and positively correlated with fibrosis stage, but not when *SPP1* was added into the regression model (Fig. 5J). In combination with our mechanistic experiments in vitro and associated mouse modeling, these data suggest that Notch-induced HSC activation and liver fibrosis are likely Opn dependent.

### Pharmacologic Notch inhibition ameliorates NASH-associated liver fibrosis


Notch inhibitors are in clinical trials for cancer (51)—the most commonly studied of these are  $\gamma$ -secretase inhibitors (GSIs) (52) that block endogenous production of NICD. We have previously shown that dibenzazepine, a well-characterized and bioavailable GSI (53), can potentially inhibit Notch signaling in vivo (15, 54). To test whether acute Notch inhibition can ameliorate NASH-associated liver fibrosis, we treated WT mice with GSI or vehicle once daily for 1 week, initiating treatment after nearly 4 months of NASH diet. Acute GSI treatment did not alter body weight, adiposity, or liver inflammation (fig. S13, A to E) but, as expected from our genetic models, lowered liver Notch activity, *Spp1* (fig. S13F), and fibrogenic gene expression (fig. S13G), with only a trend toward less fibrosis (fig. S13H). These data imply that 1 week of GSI exposure is insufficient to reverse liver fibrosis, so next, we used a chronic, intermittent dosing strategy at a lower GSI dose to mitigate potential toxicity (Fig. 6A). As previously observed (55), chronic GSI treatment lowered body weight, adiposity, and liver Notch activity (fig. S14, A and B, and Fig. 6B) and was sufficient to reduce HSC activation and liver fibrosis (Fig. 6, C and D), without effects on inflammation (fig. S14, C and D).

Unfortunately, chronic GSI treatment induces goblet cell metaplasia (53), even at the lower dose we used here (fig. S14E). Resultant intestinal toxicity likely precludes repurposing GSIs for NASH. Thus, we developed a liver-selective  $\gamma$ -secretase antagonist to bypass intestinal distribution—*Ncst* ASO (26). On the basis of preclinical data with ASOs of similar chemistry (56–58), we predicted that weekly administration of *Ncst* ASO would be well tolerated and would effectively block liver Notch signaling as compared to control ASO. Weekly *Ncst* ASO dosing of NASH diet-fed WT mice (Fig. 6E) reduced liver *Ncst*, Notch activity, and *Spp1* expression (Fig. 6F) as compared to control ASO-treated mice. *Ncst* ASO did not affect liver TUNEL staining (Fig. 6G), serum transaminases, or liver inflammation (fig. S14, F to I) but effectively reduced expression of HSC markers and collagen deposition (Fig. 6, H and I). *Ncst* ASO lowered body weight and adiposity (fig. S14, J and K), likely because of adipose ASO uptake (59), but showed no intestinal toxicity (fig. S14L), in contrast to chronic GSI dosing. Control ASO had no effect (fig. S15). These proof-of-principle studies echo data from Notch loss-of-function mice,





**Fig. 5. Notch-induced hepatocyte Opn activates HSCs and induces liver fibrosis.** (A) Hepatocyte *Spp1* expression ( $n = 4$  per group) and (B) Opn secreted in hepatocyte CM from control or Notch-activated hepatocytes transfected with siRNA directed against *Spp1* (siSpp1) or scrambled control. Expression of fibrogenic genes in HSCs exposed to CM (C) from control or Notch-activated siSpp1-transfected hepatocytes ( $n = 3$  per group) or (D) CM pretreated with an Opn-neutralizing antibody (Opn Ab;  $n = 3$  per group). (E) *Rosa<sup>NICD</sup>* mice (8 weeks old) were fed with NASH diet for 8 weeks and then transduced with AAV8-TBG-Gfp or AAV8-TBG-Cre (to generate control and L-NICD mice, respectively) and simultaneously with AAV8-H1-Gfp or AAV8-H1-shSpp1 ( $n = 7$  to 9 per group). (F) *Spp1* and (G) fibrogenic gene expression and (H) collagen staining and quantification in livers from control and L-NICD mice transduced with shSpp1 (short hairpin-mediated RNA-transfected *Spp1*). \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  as compared to the indicated controls by one-way ANOVA, followed by post hoc *t* tests (more than two groups). All data are shown as the means ± SEM. (I) Correlation between *HES1* and *SPP1* expression in liver biopsies from patients at risk of NASH ( $n = 159$ ). (J) Table of association between *HES1* expression and liver fibrosis stage after adjustment for key demographic variables (left column) or when additionally adjusted for *SPP1* expression (right column). Expression of *HES1* and *SPP1* was log transformed to ensure the assumption of normal distribution. All data in the table are shown as the regression estimates ± SD and *P* values, which were generated by multivariate ordinal regression analyses. BMI, body mass index; IFG, impaired fasting glucose; T2DM, type 2 diabetes mellitus.



**Fig. 6. Pharmacologic Notch inhibitors ameliorate NASH diet-induced fibrosis.** (A) WT mice received vehicle or GSI (5 μmol/kg of body weight) every other day for the last 3 weeks of NASH diet feeding ( $n = 8$  to 9 per group). (B) Expression of Notch targets and (C) fibrogenic genes and (D) collagen staining and quantification in livers from vehicle or GSI-treated mice. (E) WT mice received weekly injections of control or *Ncst* ASO (25 mg/kg of body weight) for the last 8 weeks of NASH diet feeding ( $n = 9$  to 10 per group). (F) *Ncst* and Notch target gene expression, (G) quantification of TUNEL staining, (H) expression of fibrogenic genes, and (I) collagen staining and quantification in livers from Control ASO- and *Ncst* ASO-treated mice. \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  as compared to the indicated controls by two-tailed *t* tests (two groups). All data are shown as the means  $\pm$  SEM.

suggesting that hepatocyte Notch activation is central to the development of obesity-induced liver fibrosis and may be therapeutically targeted in NASH (fig. S16).

## DISCUSSION

Fibrosis, although not a diagnostic determinant of NASH, predisposes to cirrhosis and liver malignancy and is the major determinant of long-term mortality of patients with NASH (8–10). NASH is projected to be the leading cause of liver transplantation because of the lack of approved therapeutics (60, 61), underscoring the urgency to uncover mechanisms of NASH-induced fibrosis to find targetable pathways. Our study demonstrates that hepatocyte Notch signaling is virtually absent in normal liver, but tracks with NASH severity in mouse and human, and is maladaptive, leading ultimately to Opn secretion and liver fibrosis. Opn is a known regulator of HSC activation, but the contribution of hepatocyte-derived Opn in NASH suggests that Notch-activated hepatocytes are not simple bystanders but rather alter the liver microenvironment to potentiate fibrosis.

To place our work in context, although several studies have suggested increased Notch activity in NPCs with CCl<sub>4</sub>-induced acute liver injury (27, 29), none has linked hepatocyte Notch to fibrosis in the setting of NASH. We hypothesize that CCl<sub>4</sub> treatment or MCD diet feeding provokes rapid hepatocellular death (27, 32), which induces Notch activation in inflammatory cells and HSCs as part of a proliferative injury response. However, these stimuli provoke minimal and/or nonsustained hepatocyte Notch activation; thus, hepatocyte-specific Notch inhibition has no impact on liver fibrosis in MCD diet-fed mice. In contrast, in the low-grade but long-term injuries associated with obesity/insulin resistance seen in NASH diet-fed mice (and in human NASH), hepatocyte Notch activity is specifically increased to cope with the chronic insult. Our proof-of-principle experiments with *Ncst* ASO highlight the potential of Notch-directed therapeutics to address NASH-associated fibrosis without the intestinal toxicity associated with systemic Notch inhibition (GSI). However, because liver-targeted Notch antagonism may be fraught with side effects including disruption of hepatic vascular integrity (62), *N*-acetylgalactosamine-modified siRNA (63, 64) or nanoparticle strategies (65) retain great potential to address the inappropriate



hepatocyte Notch activity in patients with NASH without affecting normal Notch activity in liver NPCs and other tissues.

Our data show that hepatocyte Notch-mediated Opn secretion can directly activate HSCs, independent of hepatocellular injury, leading to excessive collagen deposition. However, our data also point to other possible paths of increased fibrosis with hepatocyte Notch activity. For instance, a subset of *L-NICD* hepatocytes adopted a biliary fate, consistent with Notch's role in bile duct development (14) and ability to promote transdifferentiation to a biliary fate (23). Although DR arises primarily from cholangiocytes in liver injury (66), because DR is associated with liver fibrosis (40–43), Notch-induced hepatocyte cell fate change may augment fibrosis in *L-NICD* mice. Hepatocyte secretion of Opn, normally a biliary marker, in response to Notch activation may suggest an incomplete transition of hepatocytes toward biliary fate. Notch loss-of-function mice, however, show unchanged DR as assessed by the CK19<sup>+</sup> cell number but still less fibrosis than controls; further, a specific knockdown of hepatocyte Opn reduces fibrosis in *L-NICD* mice. Thus, our data support the conclusion that hepatocyte Notch activity facilitates liver fibrosis in NASH by both direct (Opn-mediated HSC activation) and possibly indirect (inflammation and DR) pathways.

There are several limitations to our study. For instance, our conclusions were derived primarily with the use of a NASH-provoking diet. Although we saw robust and reproducible diet-induced obesity, liver inflammation, and fibrosis across cohorts, additional studies are necessary to determine whether this diet accurately models NASH pathogenesis. Further, there may be additional Notch-regulated factors involved in the pathogenesis of NASH/fibrosis yet to be identified, and future work is necessary to isolate the upstream signal leading to hepatocyte Notch activation in NASH. Last, although we find an association between hepatocyte Notch activation and NASH severity and therapeutic outcome in patients, it is important to recognize that all intervention studies were performed in mouse models, and the potential translational relevance of Notch inhibitors in human NASH and fibrosis requires formal testing. Nevertheless, we believe that these data provide strong impetus to develop hepatocyte-specific Notch inhibitors to treat the burgeoning health crisis of NASH-associated fibrosis.

## MATERIALS AND METHODS

### Study design

The objectives of this study were to (i) determine what cell type in liver is responsible for increased Notch activation seen in patients with NASH, (ii) define what role Notch activation plays in NASH-associated fibrosis development by combining a dietary mouse model of NASH with Notch loss- (*L-DNMAM* and *L-Ncst*) and gain-of-function (*L-NICD*) transgenic mice, (iii) define the fibrogenic machinery downstream of hepatocyte Notch activation by coculture of primary hepatocytes and stellate cells in vitro and the AAV-mediated knockdown approach in vivo with validation from translational studies in patients with NASH, and (iv) determine whether pharmacologic Notch inhibition can ameliorate NASH-induced fibrosis in mice.

All data presented here have been replicated in independent cohorts of mice or in at least three biological replicates for in vitro experiments, with all staining data quantitatively analyzed by Zen software. Statistical significance was performed by Student's *t* test

or ANOVA, followed by post hoc *t* tests for multiple comparisons. On the basis of predicted effects of Notch activation on various pathologic metrics in mice, with a power of 0.8 and  $P < 0.05$ , we calculated a sample size necessary of between 6 and 11 mice per group. Animals were randomly allocated into control and experimental groups, with the group assignment recorded in a master spreadsheet and only unmasked when all samples of the respective experiments were analyzed. Human samples were obtained from a completed randomized, controlled trial (PIVENS) or a cross-sectional study for which randomization was not applicable—group assignments and other demographic information were blinded to the investigators until after all data were obtained. Data collection of each experiment was detailed in the respective figures, figure legends, and methods. No data were excluded from studies in this manuscript.

### Human liver biopsies

#### Cross-sectional HES1 staining

Normal ( $n = 3$ ), SS ( $n = 3$ ), and NASH liver ( $n = 4$ ) sections were obtained from morbidly obese individuals who underwent liver biopsy at the time of bariatric surgery to assess liver histopathology. The protocol was approved by the Ethical Committee of the Fondazione Institute for Research, Hospitalization and Health Care of Milan, and each patient signed a written informed consent.

#### PIVENS trial

We analyzed liver gene expression of *HES1* and *HEY1* and performed immunostaining of HES1 and HNF4 $\alpha$  using liver biopsy samples from PIVENS trial. PIVENS is a NASH treatment trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and conducted by the NASH Clinical Research Network (CRN). The PIVENS trial study design has been described, and the ClinicalTrials.gov identifier is NCT00063622.

#### Cross-sectional gene expression analysis in patients with suspected NASH

We analyzed liver gene expression of *HES1* and *SPPI* in individuals who underwent liver biopsy for suspected NASH because of the presence of persistent elevations in liver enzymes or because of severe obesity (67). The protocol was approved by the Ethical Committee of the Fondazione IRCCS of Milan, and each patient signed a written informed consent. For statistical analysis, comparisons were made by fitting data to generalized linear models, unadjusted (univariate analyses), or considering the following as independent variables: age, gender, body mass index, presence of impaired fasting glucose, or type 2 diabetes. Hepatic *HES1* and *SPPI* mRNA expression was normalized to *ACTB* expression and natural log transformed before analyses to ensure a normal distribution.

### Animal studies

Homozygous *Rosa*<sup>DNMAM</sup> (22), *Rosa*<sup>NICD</sup> (33), and Notch-Venus (21) male mice were crossed with female C57BL/6J (strain no. 000664, The Jackson Laboratory) mice to generate heterozygous transgenic mice for experiments. *Ncst*<sup>fllox/fllox</sup> mice (25) were crossed with albumin-*Cre* mice (68) to generate *L-Ncst* mice. All strains were maintained on C57BL/6J genetic background. Mice were weaned to standard chow (PicoLab rodent diet 20, no. 5053) for all experiments and then started on NASH diet (TD.160785, Teklad) with fructose-containing drinking water (23.1 g of fructose and 18.9 g of glucose dissolved in 1 liter of water and then filter sterilized) or MCD diet (no. 518810GI, Dyets) at 8 weeks of age, unless otherwise noted. Animals were housed in standard cages at 22°C in a 12-hour light/12-hour



dark cycle and monitored for overall well-being and signs of distress with body weight measured weekly. Upon completion of each study, all mice were weighed and euthanized. Blood was collected via cardiac puncture. Perigonadal adipose tissues were removed and weighed. Livers were weighed, excised, and split for fixation, RNA, and protein isolation and were frozen for future analyses. The Columbia University Institutional Animal Care and Use Committee approved all animal procedures.

## Statistical analysis

Results are shown as means  $\pm$  SEM unless indicated otherwise. Statistical analysis was performed using Prism software (version 6, GraphPad Software). Differences between two groups were calculated using a two-tailed Student's *t* test. Analysis involving multiple groups was performed using one-way ANOVA, followed by post hoc *t* tests. Risk factors for fibrosis severity (stages 0 to 4) in patients were evaluated by multivariate ordinal regression analysis. *HES1* and *SPP1* expression in the cross-sectional study was log transformed to ensure the assumption of normal distribution.  $P < 0.05$  was considered statistically significant.

## SUPPLEMENTARY MATERIALS

www.sciencetranslationalmedicine.org/cgi/content/full/10/468/eaat0344/DC1

### Materials and Methods

Fig. S1. *HES1* in  $\alpha$ SMA<sup>+</sup> myofibroblasts and CK7<sup>+</sup> cholangiocytes in human livers.

Fig. S2. NASH diet feeding induces steatohepatitis and fibrosis in WT mice.

Fig. S3. Characterization of NASH diet-fed *L-DNMM* mice.

Fig. S4. Characterization of NASH diet-fed *L-Ncst* mice.

Fig. S5. Characterization of *L-DNMM* mice on NASH diet for 32 weeks.

Fig. S6. Hepatocyte Notch loss of function does not protect from MCD-induced liver fibrosis.

Fig. S7. Characterization of NASH diet-fed Notch gain-of-function mice.

Fig. S8. Characterization of chow-fed *L-NICD* male mice.

Fig. S9. Characterization of chow-fed *L-NICD* female mice.

Fig. S10. Loss of hepatocyte Notch activity does not affect DRs.

Fig. S11. Hepatocyte Notch activity regulates *Spp1* and *Sox9* expression.

Fig. S12. Additional characterization of AAV8-H1-sh*Spp1*-transduced mice.

Fig. S13. Characterization of GSI-treated, NASH diet-fed mice.

Fig. S14. Additional characterization of GSI- and ASO-treated mice.

Fig. S15. Comparison of saline- and control ASO-treated mice.

Fig. S16. Model of hepatocyte Notch action to increase NASH-associated fibrosis.

Table S1. Demographic and clinical features of PIVENS patients.

Table S2. Demographic and clinical features of patients with suspected NASH.

Table S3. Sequences of quantitative polymerase chain reaction primers used in the experiments.

References (69–76)

## REFERENCES AND NOTES

- P. Hossain, B. Kavar, M. El Nahas, Obesity and diabetes in the developing world—A growing challenge. *N. Engl. J. Med.* **356**, 213–215 (2007).
- M. Lazo, J. M. Clark, The epidemiology of nonalcoholic fatty liver disease: A global perspective. *Semin. Liver Dis.* **28**, 339–350 (2008).
- C. L. Ogden, M. D. Carroll, C. D. Fryar, K. M. Flegal, Prevalence of obesity among adults and youth: United States, 2011–2014. *NCHS data brief* **28**, 339–350 (2015).
- Z. M. Younossi, M. Stepanova, M. Afendy, Y. Fang, Y. Younossi, H. Mir, M. Srishord, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin. Gastroenterol. Hepatol.* **9**, 524–530.e1 (2011).
- E. M. Brunt, Pathology of nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol. Hepatol.* **7**, 195–203 (2010).
- S. Gawrieh, N. Chalasani, Pharmacotherapy for nonalcoholic fatty liver disease. *Semin. Liver Dis.* **35**, 338–348 (2015).
- D. Kim, W. R. Kim, H. J. Kim, T. M. Therneau, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology* **57**, 1357–1365 (2013).
- P. S. Dulai, S. Singh, J. Patel, M. Soni, L. J. Prokop, Z. Younossi, G. Sebastiani, M. Ekstedt, H. Hagström, P. Nasr, P. Stål, V. W. Wong, S. Kechagias, R. Hultcrantz, R. Loomba, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Hepatology* **65**, 1557–1565 (2017).
- P. Angulo, D. E. Kleiner, S. Dam-Larsen, L. A. Adams, E. S. Björnsson, P. Charatcharoenwittaya, P. R. Mills, J. C. Keach, H. D. Lafferty, A. Stahler, S. Hafidaddottir, F. Bendtsen, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* **149**, 389–397.e10 (2015).
- M. Ekstedt, H. Hagström, P. Nasr, M. Fredrikson, P. Stål, S. Kechagias, R. Hultcrantz, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* **61**, 1547–1554 (2015).
- M. E. Fortini, D. Bilder, Endocytic regulation of Notch signaling. *Hepatology* **19**, 323–328 (2009).
- B. De Strooper, Nicastrin: Gatekeeper of the gamma-secretase complex. *Cell* **122**, 318–320 (2005).
- V. Bolós, J. Grego-Bessa, J. L. de la Pompa, Notch signaling in development and cancer. *Endocr. Rev.* **28**, 339–363 (2007).
- Y. Zong, B. Z. Stanger, Molecular mechanisms of liver and bile duct development. *Wiley Interdiscip. Rev. Dev. Biol.* **1**, 643–655 (2012).
- U. B. Pajvani, C. J. Shawber, V. T. Samuel, A. L. Birkenfeld, G. I. Shulman, J. Kitajewski, D. Accili, Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. *Nat. Med.* **17**, 961–967 (2011).
- L. Valenti, R. M. Mendoza, R. Rametta, M. Maggioni, C. J. Kitajewski, C. J. Shawber, U. B. Pajvani, Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. *Diabetes* **62**, 4052–4062 (2013).
- A. J. Sanyal, N. Chalasani, K. V. Kowdley, A. McCullough, A. M. Diehl, N. M. Bass, B. A. Neuschwander-Tetri, J. E. Lavine, J. Tonascia, A. Unalp, M. Van Natta, J. Clark, E. M. Brunt, D. E. Kleiner, J. H. Hoofnagle, P. R. Robuck, Nash CRN, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N. Engl. J. Med.* **362**, 1675–1685 (2010).
- N. P. Chalasani, A. J. Sanyal, K. V. Kowdley, P. R. Robuck, J. Hoofnagle, D. E. Kleiner, A. Unalp, J. Tonascia, NASH CRN Research Group, Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. *Contemp. Clin. Trials* **30**, 88–96 (2009).
- X. Wang, Z. Zheng, J. M. Caviglia, K. E. Corey, T. M. Herfel, B. Cai, R. Masia, R. T. Chung, J. H. Lefkowitz, R. F. Schwabe, I. Tabas, Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. *Cell Metab.* **24**, 848–862 (2016).
- D. E. Kleiner, E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell, Y. C. Liu, M. S. Torbenson, A. Unalp-Arida, M. Yeh, A. J. McCullough, A. J. Sanyal, Nonalcoholic Steatohepatitis Clinical Research Network, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* **41**, 1313–1321 (2005).
- S. Nowotzschin, P. Xenopoulos, N. Schrodde, A.-K. Hadjantonakis, A bright single-cell resolution live imaging reporter of Notch signaling in the mouse. *BMC Dev. Biol.* **13**, 15 (2013).
- L. Tu, T. C. Fang, D. Artis, O. Shestova, S. E. Pross, I. Maillard, W. S. Pear, Notch signaling is an important regulator of type 2 immunity. *J. Exp. Med.* **202**, 1037–1042 (2005).
- K. Yanger, Y. Zong, L. R. Maggs, S. N. Shapira, R. Maddipati, N. M. Aiello, S. N. Thung, R. G. Wells, L. E. Greenbaum, B. Z. Stanger, Robust cellular reprogramming occurs spontaneously during liver regeneration. *Genes Dev.* **27**, 719–724 (2013).
- X. Mu, R. Español-Suñer, I. Mederacke, S. Affò, R. Manco, C. Sempoux, F. P. Lemaigre, A. Adili, D. Yuan, A. Weber, K. Unger, M. Heikenwälder, I. A. Leclercq, R. F. Schwabe, Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. *J. Clin. Invest.* **125**, 3891–3903 (2015).
- K. Tabuchi, G. Chen, T. C. Südhof, J. Shen, Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration. *J. Neurosci.* **29**, 7290–7301 (2009).
- K. Kim, I. J. Goldberg, M. J. Graham, M. Sundaram, E. Bertaggia, S. X. Lee, L. Qiang, R. A. Haeusler, D. Metzger, P. Chambon, Z. Yao, H. N. Ginsberg, U. B. Pajvani,  $\gamma$ -secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor. *Cell Metab.* **27**, 816–827.e14 (2018).
- Y. Chen, S. Zheng, D. Qi, S. Zheng, J. Guo, S. Zhang, Z. Weng, Inhibition of notch signaling by a  $\gamma$ -secretase inhibitor attenuates hepatic fibrosis in rats. *PLOS ONE* **7**, e46512 (2012).
- R. Bansal, J. van Baaren, G. Storm, J. Prakash, The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. *Sci. Rep.* **5**, 18272 (2015).
- F. He, F. C. Guo, Z. Li, H. C. Yu, P. F. Ma, J. L. Zhao, L. Feng, W. N. Li, X. W. Liu, H. Y. Qin, K. F. Dou, H. Han, Myeloid-specific disruption of recombination signal binding protein Jk ameliorates hepatic fibrosis by attenuating inflammation through cylindromatosis in mice. *Hepatology* **61**, 303–314 (2015).
- L. Hebbard, J. George, Animal models of nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol. Hepatol.* **8**, 35–44 (2011).
- M. E. Rinella, R. M. Green, The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. *J. Hepatol.* **40**, 47–51 (2004).

32. C. M. Morell, R. Fiorotto, M. Meroni, A. Raizner, B. Torsello, M. Cadamuro, G. Spagnuolo, E. Kaffé, S. Sutti, E. Albano, M. Strazzabosco, Notch signaling and progenitor/ductular reaction in steatohepatitis. *PLoS One* **12**, e0187384 (2017).
33. L. C. Murtaugh, B. Z. Stanger, K. M. Kwan, D. A. Melton, Notch signaling controls multiple steps of pancreatic differentiation. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 14920–14925 (2003).
34. J. J. Pan, M. B. Fallon, Gender and racial differences in nonalcoholic fatty liver disease. *World J. Hepatol.* **6**, 274–283 (2014).
35. M. V. Machado, A. M. Diehl, Pathogenesis of nonalcoholic steatohepatitis. *Gastroenterology* **150**, 1769–1777 (2016).
36. T. Hardy, F. Oakley, Q. M. Anstee, C. P. Day, Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. *Annu. Rev. Pathol.* **11**, 451–496 (2016).
37. J. P. Iredale, Hepatic stellate cell behavior during resolution of liver injury. *Semin. Liver Dis.* **21**, 427–436 (2001).
38. S. L. Friedman, Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. *Physiol. Rev.* **88**, 125–172 (2008).
39. D. Yimlamai, C. Christodoulou, G. G. Galli, K. Yanger, B. Pepe-Mooney, B. Gurung, K. Shrestha, P. Cahan, B. Z. Stanger, F. D. Camargo, Hippo pathway activity influences liver cell fate. *Cell* **157**, 1324–1338 (2014).
40. X. Wang, A. Lopategi, X. Ge, Y. Lu, N. Kitamura, R. Urtasun, T. M. Leung, M. I. Fiel, N. Nieto, Osteopontin induces ductular reaction contributing to liver fibrosis. *Gut* **63**, 1805–1818 (2014).
41. M. V. Machado, G. A. Michelotti, T. A. Pereira, G. Xie, R. Premont, H. Cortez-Pinto, A. M. Diehl, Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. *J. Hepatol.* **63**, 962–970 (2015).
42. M. J. Williams, A. D. Clouston, S. J. Forbes, Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. *Gastroenterology* **146**, 349–356 (2014).
43. M. M. Richardson, J. R. Jonsson, E. E. Powell, B. A. Neuschwander-Tetri, P. S. Bhathal, J. B. Dixon, M. D. Weltman, H. Tilg, A. R. Moschen, D. M. Purdie, A. J. Demetris, A. D. Clouston, Progressive fibrosis in nonalcoholic steatohepatitis: Association with altered regeneration and a ductular reaction. *Gastroenterology* **133**, 80–90 (2007).
44. I. Mederacke, C. C. Hsu, J. S. Troeger, P. Huebener, X. Mu, D. H. Dapito, J. P. Pradere, R. F. Schwabe, Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nat. Commun.* **4**, 2823 (2013).
45. W. K. Syn, S. S. Choi, E. Liaskou, G. F. Karaca, K. M. Agboola, Y. H. Oo, Z. Mi, T. A. Pereira, M. Zdanowicz, P. Malladi, Y. Chen, C. Moylan, Y. Jung, S. D. Bhattacharya, V. Teaberry, A. Omenetti, M. F. Abdelmalek, C. D. Guy, D. H. Adams, P. C. Kuo, G. A. Michelotti, P. F. Whittington, A. M. Diehl, Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. *Hepatology* **53**, 106–115 (2011).
46. R. Urtasun, A. Lopategi, J. George, T.-M. Leung, Y. Lu, X. Wang, X. Ge, M. I. Fiel, N. Nieto, Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin  $\alpha\beta_3$  engagement and PI3K/pAkt/NF $\kappa$ B signaling. *Hepatology* **55**, 594–608 (2012).
47. J. D. Coombes, M. Swiderska-Syn, L. Dollé, D. Reid, B. Eksteen, L. Claridge, M. A. Briones-Orta, S. Shetty, Y. H. Oo, A. Riva, S. Chokshi, S. Papa, Z. Mi, P. C. Kuo, R. Williams, A. Canbay, D. H. Adams, A. M. Diehl, L. A. van Grunsven, S. S. Choi, W. K. Syn, Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. *Gut* **64**, 1120–1131 (2015).
48. A. Sahai, P. Malladi, H. Melin-Aldana, R. M. Green, P. F. Whittington, Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. *Am. J. Physiol. Gastrointest. Liver Physiol.* **287**, G264–G273 (2004).
49. Y. Zong, A. Panikkar, J. Xu, A. Antoniou, P. Raynaud, F. Lemaigre, B. Z. Stanger, Notch signaling controls liver development by regulating biliary differentiation. *Development* **136**, 1727–1739 (2009).
50. Q. Shen, S. Christakos, The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. *J. Biol. Chem.* **280**, 40589–40598 (2005).
51. I. Espinoza, L. Miele, Notch inhibitors for cancer treatment. *Pharmacol. Ther.* **139**, 95–110 (2013).
52. N. Takebe, D. Nguyen, S. X. Yang, Targeting notch signaling pathway in cancer: Clinical development advances and challenges. *Pharmacol. Ther.* **141**, 140–149 (2014).
53. J. H. van Es, M. E. van Gijn, O. Riccio, M. van den Born, M. Vooijs, H. Begthel, M. Cozijnsen, S. Robine, D. J. Winton, F. Radtke, H. Clevers, Notch/ $\gamma$ -secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. *Nature* **435**, 959–963 (2005).
54. D. P. Sparling, J. Yu, K. Kim, C. Zhu, S. Brachs, A. L. Birkenfeld, U. B. Pajvani, Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity. *Mol. Metab.* **5**, 113–121 (2016).
55. P. Bi, T. Shan, W. Liu, F. Yue, X. Yang, X. R. Liang, J. Wang, J. Li, N. Carlesso, X. Liu, S. Kuang, Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. *Nat. Med.* **20**, 911–918 (2014).
56. D. Gaudet, D. Brisson, K. Tremblay, V. J. Alexander, W. Singleton, S. G. Hughes, R. S. Geary, B. F. Baker, M. J. Graham, R. M. Crooke, J. L. Witztum, Targeting APOC3 in the familial chylomicronemia syndrome. *N. Engl. J. Med.* **371**, 2200–2206 (2014).
57. M. J. Graham, R. G. Lee, T. A. Bell III, W. Fu, A. E. Mullick, V. J. Alexander, W. Singleton, N. Viney, R. Geary, J. Su, B. F. Baker, J. Burkey, S. T. Crooke, R. M. Crooke, Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. *Circ. Res.* **112**, 1479–1490 (2013).
58. D. Gaudet, V. J. Alexander, B. F. Baker, D. Brisson, K. Tremblay, W. Singleton, R. S. Geary, S. G. Hughes, N. J. Viney, M. J. Graham, R. M. Crooke, J. L. Witztum, J. D. Brunzell, J. J. Kastelein, Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. *N. Engl. J. Med.* **373**, 438–447 (2015).
59. R. S. Geary, D. Norris, R. Yu, C. F. Bennett, Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. *Adv. Drug Deliv. Rev.* **87**, 46–51 (2015).
60. A. Suzuki, A. M. Diehl, Nonalcoholic Steatohepatitis. *Annu. Rev. Med.* **68**, 85–98 (2017).
61. M. E. Rinella, Nonalcoholic fatty liver disease: A systematic review. *JAMA* **313**, 2263–2273 (2015).
62. H. Cuervo, C. M. Nielsen, D. A. Simonetto, L. Ferrell, V. H. Shah, R. A. Wang, Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice. *Hepatology* **64**, 1302–1316 (2016).
63. A. Wittup, J. Lieberman, Knocking down disease: A progress report on siRNA therapeutics. *Nat. Rev. Genet.* **16**, 543–552 (2015).
64. C. Lorenzer, M. Dirin, A. M. Winkler, V. Baumann, J. Winkler, Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. *J. Control. Release* **203**, 1–15 (2015).
65. D. Dehaini, R. H. Fang, L. Zhang, Biomimetic strategies for targeted nanoparticle delivery. *Bioeng. Transl. Med.* **1**, 30–46 (2016).
66. S. Jörs, P. Jeliakova, M. Ringelhan, J. Thalhammer, S. Dürli, J. Ferrer, M. Sander, M. Heikenwalder, R. M. Schmid, J. T. Siveke, F. Geisler, Lineage fate of ductular reactions in liver injury and carcinogenesis. *J. Clin. Invest.* **125**, 2445–2457 (2015).
67. R. M. Mancina, P. Dongiovanni, S. Petta, P. Pingitore, M. Meroni, R. Rametta, J. Borén, T. Montalcini, A. Pujia, O. Wiklund, G. Hindy, R. Spagnuolo, B. M. Motta, R. M. Pipitone, A. Craxi, S. Fargion, V. Nobili, P. Kälälä, V. Kärjä, V. Männistö, J. Pihlajamäki, D. F. Reilly, J. Castro-Perez, J. Kozlitina, L. Valenti, S. Romeo, The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. *Gastroenterology* **150**, 1219–1230.e6 (2016).
68. C. Postic, M. A. Magnuson, DNA excision in liver by an albumin-Cre transgene occurs progressively with age. *Genesis* **26**, 149–150 (2000).
69. U. B. Pajvani, L. Qiang, T. Kangsamaksin, J. Kitajewski, H. N. Ginsberg, D. Accili, Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTORC1 stability. *Nat. Med.* **19**, 1055–1060 (2013).
70. C. M. Miller, M. Tanowitz, A. J. Donner, T. P. Prakash, E. E. Swayze, E. N. Harris, P. P. Seth, Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver. *Nucleic Acid Res.* **28**, 119–127 (2018).
71. L. Lisowski, A. P. Dane, K. Chu, Y. Zhang, S. C. Cunningham, E. M. Wilson, S. Nygaard, M. Grompe, I. E. Alexander, M. A. Kay, Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. *Nature* **506**, 382–386 (2014).
72. K. Kim, L. Qiang, M. S. Hayden, D. P. Sparling, N. H. Purcell, U. B. Pajvani, mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2. *Nat. Commun.* **7**, 10255 (2016).
73. J. Font-Burgada, S. Shalapour, S. Ramaswamy, B. Hsueh, D. Rossell, A. Umehara, K. Taniguchi, H. Nakagawa, M. A. Valasek, L. Ye, J. L. Kopp, M. Sander, H. Carter, K. Deisseroth, I. M. Verma, M. Karin, Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. *Cell* **162**, 766–779 (2015).
74. I. Mederacke, D. H. Dapito, S. Affò, H. Uchinami, R. F. Schwabe, High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. *Nat. Protoc.* **10**, 305–315 (2015).
75. J. Folch, M. Lees, G. H. Sloane Stanley, A simple method for the isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* **226**, 497–509 (1957).
76. J. P. Pradere, J. Kluwe, S. De Minicis, J. J. Jiao, G. Y. Gwak, D. H. Dapito, M. K. Jang, N. D. Guenther, I. Mederacke, R. Friedman, A. C. Dragomir, C. Aloman, R. F. Schwabe, Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. *Hepatology* **58**, 1461–1473 (2013).

**Acknowledgments:** We thank A. Flete, T. Kolar, and J. Weber for excellent technical support; W. Wang, L. Lu, S. Shah, and S. Ho for assistance with cell sorting; and members of the Pajvani, Tabas, and Schwabe laboratories for insightful discussion. We also acknowledge J. Clarke and N. Cherrington (Arizona) and N. Tanaka and F. Gonzalez (NIH) for sharing samples related to this work, H. Grajal and J. Kitajewski (UIC) for sharing mouse strains, and the Ancillary Studies Committee and Publications and Presentations Committee of the NASH CRN, who reviewed and approved this manuscript. **Funding:** This work was supported by NIH DK103818 (to U.B.P.), NIH DK105303 (to U.B.P.), MyFIRST AICR Grant no. 16888 (to L.V.), ALF Liver Scholar Award (to X.W.), and an AHA Predoctoral fellowship 17PRE33120000 (to C.Z.). Cell sorting

experiments were performed in the CCTI Flow Cytometry Core, supported by NIH S10OD020056, and the Diabetes and Endocrinology Research Center Flow Core Facility funded in part through NIH 5P30DK063608. The PIVENS trial was supported by NIH U01DK061734 and U01DK061730. **Author contributions:** C.Z. designed, performed, and interpreted experiments and wrote the manuscript. K.K., X.W., A.B., M.S., P.D., M.M., K.P.Y., A.M.D., R.F.S., I.T., L.V., and J.E.L. performed and interpreted experiments. M.J.G. designed and provided *Ncst* ASO. U.B.P. designed and interpreted experiments and wrote the manuscript. **Competing interests:** The authors declare that they have no competing financial interests. **Data and materials availability:** All data associated with this study are present in the manuscript and the Supplementary Materials.

Submitted 17 January 2018  
Resubmitted 3 June 2018  
Accepted 31 October 2018  
Published 21 November 2018  
10.1126/scitranslmed.aat0344

**Citation:** C. Zhu, K. Kim, X. Wang, A. Bartolome, M. Salomao, P. Dongiovanni, M. Meroni, M. J. Graham, K. P. Yates, A. M. Diehl, R. F. Schwabe, I. Tabas, L. Valenti, J. E. Lavine, U. B. Pajvani, Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. *Sci. Transl. Med.* **10**, eaat0344 (2018).



## Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Changyu Zhu, KyeongJin Kim, Xiaobo Wang, Alberto Bartolome, Marcela Salomao, Paola Dongiovanni, Marica Meroni, Mark J. Graham, Katherine P. Yates, Anna Mae Diehl, Robert F. Schwabe, Ira Tabas, Luca Valenti, Joel E. Lavine and Utpal B. Pajvani

*Sci Transl Med* 10, eaat0344.  
DOI: 10.1126/scitranslmed.aat0344

### Taking liver fibrosis down a Notch

Nonalcoholic steatohepatitis (NASH) is a liver disease characterized by fat accumulation, inflammation, and liver cell damage. Here, Zhu *et al.* focused on Notch signaling in NASH and associated liver fibrosis. Expression of Notch target genes was increased in liver biopsies from patients with more severe NASH, and a mouse model of diet-induced NASH showed increased hepatocyte Notch expression. Notch signaling activated hepatic stellate cells, leading to liver fibrosis. Inhibiting Notch signaling using a liver-targeted antisense oligonucleotide reduced liver fibrosis in a diet-induced NASH mouse model. This study suggests that targeting hepatocyte Notch signaling could be therapeutic for NASH-associated liver fibrosis.

#### ARTICLE TOOLS

<http://stm.sciencemag.org/content/10/468/eaat0344>

#### SUPPLEMENTARY MATERIALS

<http://stm.sciencemag.org/content/suppl/2018/11/19/10.468.eaat0344.DC1>

#### RELATED CONTENT

<http://stm.sciencemag.org/content/scitransmed/8/357/357ra122.full>  
<http://stm.sciencemag.org/content/scitransmed/8/323/323rv1.full>  
<http://stm.sciencemag.org/content/scitransmed/9/396/eaal3694.full>  
<http://stm.sciencemag.org/content/scitransmed/9/405/eaai8710.full>  
<http://stm.sciencemag.org/content/scitransmed/10/454/eaan1230.full>

#### REFERENCES

This article cites 76 articles, 11 of which you can access for free  
<http://stm.sciencemag.org/content/10/468/eaat0344#BIBL>

#### PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)